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Eighty adult patients with acute myeloid leukemia (AML) received peripheral blood T cellereplete HLA
haploidentical hematopoietic stem cell transplantation (haplo-HSCT). Disease status at transplantation was
either ﬁrst or second complete remission (CR, n ¼ 69) or relapse/refractory (n ¼ 11). Identical transplant-
related procedures with conditioning regimen consisting of fractionated 800 cGy total body irradiation
(TBI), ﬂudarabine (30 mg/m2/day for 5 days), busulfan (3.2 mg/kg/day for 2 days), and antithymocyte globulin
(1.25 mg/kg/day on days 4 to 1) and graft-versus-host disease (GVHD) prophylaxis with tacrolimus and
methotrexate were used in all patients. Recovery of neutrophil (median, 11 days) and platelet (median, 10
days) counts was achieved in all patients with full donor chimerism (99%), and no delayed engraftment
failure was observed. The cumulative incidence of grades III to IV acute GVHD and moderate to severe chronic
GVHD was 11.2% and 26.3%, respectively. A donor CD8þ and CD4þ T cell dose above the median value was
signiﬁcantly associated with the incidences of grades II to IV acute GHVD and moderate to severe chronic
GVHD, respectively. After a median follow-up of 28 months for survivors, the 2-year cumulative incidences of
relapse (n ¼ 20) and nonrelapse mortality (n ¼ 10) were 26.6% and 12.2%, respectively. Although all but 1
patient in relapse/refractory status died, the 2-year overall and progression-free survival of patients in ﬁrst CR
was 82.5% and 75.1%, respectively. We suggest the strategy of fractionated 800 cGy TBI-based conditioning
with unmanipulated peripheral blood stem cell grafts seems feasible with favorable outcomes for adult pa-
tients with AML undergoing haplo-HSCT in CR.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION transplantation [1-3]. Haploidentical HSCT (haplo-HSCT) is
Although hematopoietic stem cell transplantation (HSCT)
provides a curative opportunity for patients with acute
myeloid leukemia (AML), identifying a compatible related or
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ty for Blood and Marrow Transplantation.an attractive strategy for these patients because it offers
advantages such as readily available donors, control of
preferred composition of graft, and timely application of
repeated stem cell donation [4,5]. Until recently, however,
haplo-HSCT has been limited by high rates of graft loss and
acute graft-versus-host disease (aGVHD) [6-10].
Starting in the early 1990s, strategies for partial T cell
depletion (TCD) were adopted to overcome the HLA barrier
and control of GVHD in the haplo-HSCT setting [11,12]. Aversa
et al. [13] pioneered the use of mega-dosed peripheral blood
stem cells (PBSCs) with ex vivo TCD after myeloablative
conditioning (MAC) in haplo-HSCT, which led to a major
advance in the achievement of a high engraftment rate
Table 1
Patient and Donor Characteristics
Characteristic Value
Median recipient age, yr (range) 41 (16-69)
Gender, male 52 (65)
Age groups, yr
16-29 16 (20)
30-49 41 (51)
50-59 8 (10)
60-69 15 (19)
AML type
De novo 73 (91)
Secondary 7 (9)
Previous transplant
No 68 (85)
Autologous 5 (6)
Allogeneic 7 (9)
AML with myeloid sarcoma at diagnosis 7 (9)
Chromosomal risk group
Favorable 17 (21)
Intermediate 50 (63)
Adverse 13 (16)
WBC at diagnosis, 109/L
Median (range) 6.86 (0.37-250.13)
50, n (%) 22 (28)
Disease status
CR1 or iCR1 52 (65)
CR2 17 (21)
Relapse/refractory 11 (14)
Median serum ferritin level at transplant, ng/mL
(range)
1122 (241-7192)
>2000, n (%) 17 (21)
Matched HLA loci
4/8 54 (68)
5/8 19 (24)
6/8 7 (9)
Median donor age, yr (range) 33 (7-61)
Donorerecipient gender matching
Maleemale 29 (36)
Maleefemale 17 (21)
Femaleefemale 11 (14)
Femaleemale 23 (29)
ABO incompatibility
Match 59 (74)
Mismatch 21 (26)
Donor relationship
Mothereson 17 (21)
Motheredaughter 6 (7)
Sonefather 24 (30)
Sonemother 15 (19)
Daughterefather 3 (4)
Daughteremother 4 (5)
Siblingesibling 11 (14)
KIR alloreactivity
Yes 20 (25)
No 60 (75)
iCR1 indicates CR with incomplete blood count recovery.
Values are number of cases with percents in parentheses, unless otherwise
indicated.
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immune reconstitution because of the few T cells in the graft
can be challenging [14,15]. Therefore, the recent de-
velopments in the approach using an adoptive transfer of
donor T regulatory cells followed by donor conventional T
cells seem very promising [16].
An alternative approach, developed at Johns Hopkins
University, of using reduced-intensity conditioning (RIC)
with post-transplantation cyclophosphamide in unmanipu-
lated marrow graft haplo-HSCT showed low nonrelapse
mortality (NRM) [17]. Outcomes were promising when the
use of high dose, post-transplantation cyclophosphamide
was combined with MAC and T cellereplete (TCR) graft for
advanced/refractory hematologic malignancies [18,19].
Recent studies have also shown the feasibility of substituting
PBSCs as a graft source in this setting [20,21]. A small pro-
spective phase II trial of MAC haplo-HSCT using TCR PBSCs
showed engraftment in all patients with relatively favorable
1-year NRM (50%) [22], whereas Kurokawa et al. [23] showed
NRM approaching 70% after TCD haplo-HSCT using a 1 Gy
total body irradiation (TBI)-based regimen. Investigators
from Peking University have consistently reported promising
results of MAC haplo-HSCT using TCR granulocyte colony-
stimulating factor (G-CSF) mobilized peripheral blood and
bone marrow grafts [24,25]. Favorable outcomes of TCR
haplo-HSCTwith a non-TBIebased RIC regimenwas reported
by Lee et al. [26] in 83 patients with AML or myelodysplastic
syndromes.
TBI-based conditioning regimens for patients with leu-
kemia receiving allogeneic HSCT are used with the intent of
eradicating residual leukemic cells and/or reducing leukemic
burden as well as for potential immunosuppressive effects
[27]. However, data regarding optimal dose requirements
and fractionation used during TBI for various transplantation
settings are relatively limited. Although 12 Gy TBI delivered
twice daily over 3 days in combination with chemotherapy
have been most commonly used for TBI-based MAC regi-
mens, we saw poor survival outcome after haplo-HSCT
following our earlier conditioning regimen, consisting of a
fractionated 12 Gy TBI plus ﬂudarabine, busulfan, and
antithymocyte globulin (ATG) [10]. Therefore, to lower the
risk of radiation-induced toxicity but allow adequate
immunosuppression and leukemic cell eradication in the
setting of unmanipulated G-CSFemobilized PBSC haplo-
HSCT, we used TBI-based conditioning regimens delivering
800 cGy twice daily over 2 days followed by ﬂudarabine,
intravenous busulfan, and ATG with the standard GVHD
prophylaxis. In this report, we analyzed 80 consecutive adult
patients with AML undergoing haplo-HSCT using this
approach to evaluate the efﬁcacy and safety of this regimen.
METHODS
Patients
Eighty consecutive adult patients with AML who received haplo-HSCT
between August 2008 and July 2013 at the Catholic Blood and Marrow
Transplantation Center were analyzed. Haplo-HSCT was offered to patients
if they had no available 7/8 HLA antigen-matched unrelated donor.
Twenty-three patients previously reported were included with further
follow-up for this analysis [28]. The median age of patients was 41 years
(range, 16 to 69), with 19% at least 60 years of age (Table 1). For patients with
better cytogenetic risk [29] transplanted in ﬁrst complete remission
(CR1; 10 of 17 subjects with inv(16)(13.1q22)/t(16;16)(p13.1;q22) or
t(8;21)(q22;q22)), reasons for transplantation were myeloid sarcoma
involving the nervous system (n ¼ 1), c-kit (n ¼ 5) or FLT3/ITD (n ¼ 1)
mutations, secondary AML (n¼ 1), high aberrant expression of CD19 (n¼ 1),
and presence of minimal residual disease after repetitive chemotherapy
(n ¼ 1). Among twenty-one of 36 patients (58%) with intermediate cyto-
genetic risk in CR1 (normal karyotype, n¼ 24; cytogenetic abnormalities notclassiﬁed as favorable or adverse, n ¼ 12), factors associated with high-risk
AML included secondary AML (n ¼ 2), refractoriness to ﬁrst-line (n ¼ 3) or
second-line (n ¼ 2) chemotherapy, hyperleukocytosis (50  109/L, [n ¼
14]), and FLT3/ITD mutation (n ¼ 4). Patients with t(9;22) or t(15;17) were
excluded.
All patients and donors had certiﬁed their fully informed consent as per
the Declaration of Helsinki. This study was approved by the institutional
review board.
Donors
Donors had a median age of 33 years (range, 7 to 61). All
donorerecipient pairs were typed for HLA-A, -B, -C, and -DR loci by high-
resolution DNA techniques. For each pair, the patient shared 1 haplotype
and mismatched the unshared haplotype with some difference in degree.
Among 42 noninherited maternal antigen (NIMA) complementary trans-
plantations [30], 19 were offspring (45%) and 23 maternal (55%) donors.
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mismatched sibling donors could not be identiﬁed. Donors who were clas-
siﬁed as natural killer alloreactive against patients possessed HLA-B and -C
killer cell immunoglobulin-like receptor (KIR) ligand(s) that were missing in
the patient. All but 1 donor and all recipients were cytomegalovirus (CMV)
seropositive at HSCT. In cases of multiple available donors, the mother had
priority under consideration of other factors, such as donor age, comor-
bidity, and ABO matching (Table 1).
Conditioning Regimen and GVHD Prophylaxis
All patients received an identical conditioning regimen composed of
800 cGy TBI (fraction size of 200 cGy given twice a day on days 9 and 8),
ﬂudarabine (30 mg/m2/day i.v. on days 7 to 3), busulfan (3.2 mg/kg/day
i.v. in 4 divided doses on days 6 and 5), and rabbit ATG (Thymoglobulin,
Sanoﬁ/Genzyme, Cambridge, MA; 1.25 mg/kg/day on days 4 to 1). A
combination of tacrolimus (i.v. continuous infusion with starting dose of .03
mg/kg from days 1 to þ21 and then p.o. at a total of .12 mg/kg/day) plus
short-course methotrexate (10 mg/m2 i.v. bolus injection on
days þ1, þ3, þ6, and þ11) was used for GVHD prophylaxis in all patients
[10]. Individualized dosage adjustment of tacrolimus was based on plasma
level to maintain a target dose of 8 to 12 ng/mL. Tacrolimus was tapered off
from day þ90 after transplant in the absence of aGVHD.
Supportive Care
Recombinant human G-CSF (5 mg/kg/day) was administered subcuta-
neously from day þ7 until neutrophil recovery. Intravenous ganciclovir (5
mg/kg twice daily) was administered during the conditioning period for
CMV prophylaxis. Serial weekly monitoring for CMV viremia using quanti-
tative PCR assays was initially started from neutrophil recovery during the
ﬁrst 3 months followed by monitoring every 2 weeks or at each follow-up
visit. Ganciclovir or foscarnet was initiated with evidence of CMV reac-
tivation deﬁned by PCR more than 500 copies/mL on 2 consecutive assays.
Recovery of lymphocyte subpopulations was assessed by ﬂow cytometry of
peripheral blood samples 1, 3, 6, 9, and 12 months after transplantation. The
strategy for other general supportive care followed a previously described
institutional protocol [31,32].
Hematopoietic Stem Cell Harvest
All donors were primed with G-CSF (10 mg/kg/day) subcutaneously for 4
to 6 consecutive days from day 4. PBSC harvesting was repeated on the
next day or 2 if the target CD34þ cell count (a minimum of 5106 cells/kg of
recipient body weight) was not reached. The collected unmanipulated graft
was infused into the recipient on the day of harvesting. The composition of
infused PBSCs was evaluated for cell surface markers using monoclonal
antibodies.
Deﬁnition
Myeloid and platelet engraftment was deﬁned as the ﬁrst of 3 consec-
utive days with an absolute neutrophil count of at least .5  109/L and theFigure 1. Cumulative incidence of myeloid (ﬁrst of 7 consecutive days with a platelet count at least 20  109/L without
transfusion, respectively. Failure to neutrophil engraftment by day þ28 was
considered primary engraftment failure. Secondary engraftment failure was
deﬁned as an initial engraftment with documented donor-derived hema-
topoiesis followed by loss of graft function. Complete (95%) donor
chimerism was evaluated at 1, 3, 6, and 12 months by PCR DNA ﬁnger-
printing of short tandem repeats on recipient peripheral T lymphocytes.
GVHDwas diagnosed and graded according to the clinical consensus criteria
[33,34].
Statistical Analysis
Categorical and continuous variables were compared using the chi
square test and Mann-Whitney test, respectively. Spearman’s rank correla-
tion coefﬁcient was used to associate graft composition and engraftment.
Graft cell doses were analyzed as categorical variables ( versus > median
value) for transplant outcome. Overall survival (OS) and progression-free
survival (PFS), assessed from the day of transplant, were estimated by the
Kaplan-Meier method and compared by the log-rank test. Probability of
relapse, NRM, and aGVHD and chronic GVHD (cGVHD; severity measures
referring to peak) were estimated using the cumulative incidence method
and compared by the Gray test. P  .05 was considered signiﬁcant. Analyses
were conducted using the SPSS, version 13.0 (SPSS, Inc., Chicago, IL) and R
software (http://cran.r-project.org/).
RESULTS
Engraftment, Graft Composition, and Recovery of T Cell
Subsets
Sustained myeloid engraftment with median 11 days
(range, 9 to 42) was achieved in all patients (60 years,
median 10 days [range, 6 to 47]), and all but 1 patient (early
NRM) had platelet recovery at median 10 days (range, 6 to
47) (Figure 1). Donor chimerism of at least 99% was
conﬁrmed in 75 of 80 patients (94%) by day þ30 and in the
remaining 5 patients within the next month. No graft loss
has occurred in the survivors so far.
The median number of CD34þ cells transplanted was
6.48  106 (range, 2.22 to 39.7  106)/kg of recipient body
weight, the median numbers of donor CD4þ cells and CD8þ
cells were 253  106 (range, 102 to 942  106)/kg and 172 
106 (range, 51.7 to 643  106)/kg, respectively. The median
number of CD3CD56þ cells was 96.7  106 (range, 16.9 to
366  106)/kg. A strong concordance was found between the
graft cell doses of CD3þ and CD4þ (P < .0001) or CD8þ (P <
.0001) as well as between CD4þ and CD8þ (P < .0001). The
CD34þ cell dose was less than the targeted dose in 42 donorsleft) and platelet (right) engraftment.
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performed in 16 donors). Higher CD34þ cell dose correlated
with signiﬁcantly less time for absolute neutrophil count
(R2 ¼ .365, P ¼ .001) recovery but only with borderline
signiﬁcance with platelet (R2 ¼ .203, P ¼ .071) recovery.
Other factors, including patient or donor age, showed no
signiﬁcant correlation with time to engraftment. On the
other hand, we found a signiﬁcantly higher number of CD4þ
cells (R2¼ .295, P¼ .008) with increasing donor age, whereas
cell doses of other graft composition showed no correlation.
This may be related to less yield of CD34þ cell collection after
the ﬁrst apheresis with a tendency toward increasing donor
age (R2¼.196, P¼ .082), which led to subsequent aphereses
to achieve the target dose.
The mean values of lymphocyte subsets are illustrated in
Figure 2. Brieﬂy, the median number of absolute CD8þ and
CD4þ T cells among assessable patients were, respectively,
22/mL and 3/mL at 1 month post-transplantation (n ¼ 64),
539/mL and 117/mL at 3 months (n ¼ 44), 1227/mL and 203/mL
at 6 months (n ¼ 23), and 1364/mL and 318/mL at 1 year post-
transplantation (n ¼ 16). As expected, the median number of
CD3CD56þ natural killer cells showed higher proportions
during the ﬁrst 6 months post-transplantation: 198/mL (n ¼
64), 404/mL (n ¼ 44), and 486/mL (n ¼ 23) at 1, 3, and 6
months after transplant, respectively. We found no signiﬁ-
cant impact of pretransplant variables on lymphocyte
reconstitution (data not shown).
GVHD
The cumulative incidences of grades II to IV (n ¼ 38) and
grades III to IV (n ¼ 9) de novo aGVHD at 100 days was 47.5%
(95% conﬁdence interval [CI], 36.2 to 58.0) and 11.2% (95% CI,
5.4 to 19.2), respectively, occurring at a median time of 20
days (range, 12 to 84) after transplantation with no late
onset. Of the 9 patients with severe aGVHD, the disease
status at transplantation was standard (CR1) in 4 patientsFigure 2. Reconstitution of lymphocyte subsets (CD8þ T cells [CD3þCD8þ], CD4þ T c
haplo-identical HSCT after fractionated 800 cGy TBI-based conditioning regimen witand advanced in 5 (CR2 [n ¼ 2] or CR3 [n ¼ 1]; relapsed/
refractory [n ¼ 2]). Patients with grade III aGVHD (n ¼ 6)
were all manageable with steroids and mycophenolate
mofetil (MMF) added to tacrolimus, although 3 of them later
showed chronic features consistent with moderate cGVHD.
Of the patients with grade IV aGVHD (n ¼ 3), 1 patient who
received etanercept after failing triple combination of
tacrolimus, steroid, and MMF is currently alive without signs
of GVHD, whereas 2 other patients died of severe infection
during treatment of GVHD.
After a median time of 3.1 months (range, .7 to 7.5), 36
patients developed cGVHD (overlap syndrome, n ¼ 14;
classic chronic, n ¼ 22) with the cumulative incidence of
45.0% (95% CI, 33.8 to 55.6), whereas that of moderate to
severe cGVHD (n¼ 21) was 26.3% (95% CI, 17.1 to 36.3). Of the
21 patients with moderate (n ¼ 19) or severe (n ¼ 2) cGVHD,
2 patients with severe cGVHD died from severe infections
and 5 patients eventually relapsed of AML during cGHVD
management. The rest of the patients (n ¼ 14) received the
combinations of tacrolimus, systemic steroid, and/or MMF,
together with localized therapy including phototherapy or
topical agents. Although 6 of 46 disease-free survivors with a
follow-up duration of more than 1 year needed immuno-
suppression after the ﬁrst year post-transplant, 22 of 50
patients who are alive in disease-free status resumed their
normal lives.
As shown in Table 2, donor CD8þ and CD4þ T cell doses
above the median value were signiﬁcantly associated with
the incidences of grades II to IV aGHVD ( versus > median
value of CD8þ, 35% versus 60%; P ¼ .021) and moderate to
severe cGVHD ( versus >median value of CD4þ, 13% versus
40%; P¼ .007), respectively (Figure 3). Because there were no
signiﬁcant associations between any pretransplant variables
and aGVHD or cGVHD, we arbitrarily performed multivariate
analyses by choosing donor age, previous transplantation,
and patient age as confounding correlates, which showedells [CD3þCD4þ], CD56þ T cells [CD3CD56þ], and B cells [CD19þ]) after TCR
h low-dose ATG. Curves represent means  standard error of the mean.
Table 2
Univariate Analysis of Donor Graft Cell Doses on Transplant Outcomes: Comparison of Recipients with Donor Cell Doses above the Median with Others
CD34þ CD3þ CD4þ CD8þ CD19þ CD3CD56þ CD3þCD56þ
Median (range)  106/kg 6.5 (2.2-39.7) 498 (201-1510) 253 (102-942) 172 (51.7-643) 129 (19-447) 96.7 (16.9-366) 37.2 (3.2-177)
Grades II-IV aGVHD
HR (95% CI)* .7 (.4-1.3) 1.8 (1.0-3.4) 1.7 (.9-3.3) 2.1 (1.1-4.1) 1.6 (.9-3.1) 1.3 (.7-3.4) .8 (.5-1.6)
P .27 .07 .09 .02 .13 .45 .58
Moderateesevere cGVHD
HR (95% CI)* .5 (.2-1.3) 2.1 (.8-5.1) 3.6 (1.3-10) 2.6 (1.0-7.0) 1.8 (.7-4.2) 2.2 (.9-5.4) 1.1 (.4-2.4)
P .16 .13 .01 .05 .20 .09 .92
CMV DNAemia
HR (95% CI)* .7 (.4-1.2) 1.6 (.9-2.7) 1.0 (.6-1.7) 1.8 (1.0-3.1) 1.6 (.9-2.7) 1.3 (.9-2.2) 1.6 (.9-2.7)
P .20 .10 .91 .04 .09 .28 .09
OS
HR (95% CI)* 2.0 (.9-4.5) 2.1 (.9-5.0) 1.8 (.8-4.1) 1.3 (.6-2.8) 1.0 (.4-2.1) .6 (.3-1.4) .8 (.4-1.8)
P .10 .08 .17 .58 .89 .23 .64
PFS
HR (95% CI)* 1.7 (.8-3.5) 1.6 (.7-3.2) 1.4 (.7-2.8) 1.1 (.6-2.3) .8 (.4-1.6) .6 (.3-1.2) .3 (.3-1.3)
P .16 .24 .40 .70 .50 .17 .17
Relapse
HR (95% CI)* 1.7 (.7-4.0) 1.2 (.5-3.0) 1.3 (.5-3.1) 1.0 (.4-2.4) .8 (.3-1.9) .7 (.3-1.6) .2 (.2-1.3)
P .26 .64 .55 .99 .58 .33 .15
NRM
HR (95% CI)* 1.5 (4.4-5.4) 2.3 (.6-8.8) 1.4 (.4-4.9) 1.5 (4.3-5.4) 1.0 (.3-3.2) .6 (.2-2.2) .9 (.3-3.3)
P .50 .22 .57 .52 .94 .48 .94
* Hazard ratio of recipients with donor cell dose above the median value compared with the others with cell dose  median.
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values were independently associated with grades II to IV
aGHVD (hazard ratio [HR], 2.4; 95% CI,1.2 to 4.9; P¼ .014) and
moderate to severe cGVHD (HR, 4.0; 95% CI, 1.5 to 11.1; P ¼
.007), respectively. Of the 42 recipients assessable for NIMA
effects, lower incidence of grades II to IV aGVHD was seen in
the group of female patients with offspring donors (n ¼ 19;
NIMA-mismatched) compared with 23 patients with
maternal donors without statistical signiﬁcance (36.8% 
11.0% versus 52.2%  10.7%, P ¼ .242).Survival
After a median follow-up of 28.0 months (range, 7.2 to
67.1) for survivors, 55 patients were alive and 25 patients
had died from NRM (n ¼ 10) or relapse (n ¼ 15). After the
post-transplant relapse, reinduction chemotherapy followed
by second allogeneic transplantation (double-cord blood
transplantation, n ¼ 3; HLA-matched unrelated trans-
plantation, n ¼ 1) were performed that left 1 patient dead
due to pneumonia, another relapsed after the second
transplantation, and 2 patients currently alive in disease-
free status. The remaining patient decided to receive con-
servative care and died. The 2-year OS and PFS rates were
66.0%  5.8% and 61.1%  5.80%, respectively, in all patients,
whereas the OS and PFS rates were signiﬁcantly different
according to disease status (Figure 4A,B). At 2 years, OS and
PFS rates of 52 patients in CR1 (n ¼ 45) or incomplete CR1
(n ¼ 7) were 82.5%  5.7% and 75.1%  7.1%, respectively,
and 78.2%  6.8% and 71.1%  7.1%, respectively, at 3 years.
Univariate analyses showed that advanced disease status at
HSCT (HR, 3.9; 95% CI, 1.9 to 8.1; P < .0001), donor age (HR,
1.03; 95% CI, 1.00 to 1.05; P ¼ .029), and occurrence of grades
III to IV aGVHD (HR, 3.1; 95% CI, 1.3 to 7.3; P ¼ .009) were
associated with worse PFS (Supplementary Table 1). Similar
factors were also signiﬁcantly associated with OS
(Supplementary Table 1). Multivariate analyses revealed
that the advanced disease status (OS, P ¼ .001; PFS, P ¼ .001)
and occurrence of aGVHD (OS, P ¼ .046; PFS, P ¼ .016) were
the only independent prognostic factors for OS and PFS
(Table 3).Relapse
Of all 80 patients, 20 patients relapsed after HSCT with
the 2-year cumulative incidence of 26.6% 5.2%. Relapsewas
ﬁrst detected on bone marrow examination routinely per-
formed every 3 months during the ﬁrst 2 years after trans-
plant (n ¼ 10) or by circulating leukemic blasts (n ¼ 8) or
development of myeloid sarcoma (n ¼ 2) conﬁrmed by
subsequent bonemarrow examination (n¼ 8). The incidence
according to disease status was 16.6%  5.5% in CR1/incom-
plete CR1, 18.2%  9.9% in CR2/CR3, and 77.3%  17.3% in
relapsed/refractory status (P < .0001; Figure 4C). Nine pa-
tients with relapsed/refractory status relapsed at a median of
5.5months (range,1.0 to 8.5), whereas patients in CR1 (n¼ 8)
and CR2/CR3 (n¼ 3) relapsed at a median time of 8.9 months
(range, 3.8 to 16.1) and 5.8 months (range, 5.3 to 9.4),
respectively. No signiﬁcant difference in 3-year relapse
incidence according to cytogenetic risk, whether better
(24.2%  10.9%), intermediate (23.6%  6.4%), or poor (41.0%
 15.4%), was shown (P¼ .413). In further univariate analysis,
advanced disease status (HR, 3.7; 95% CI, 1.6 to 8.9; P ¼ .003)
andWBC count greater than 50  109/L at diagnosis (HR, 2.2;
95% CI, .9 to 5.3; P ¼ .07) were signiﬁcantly associated with
incidence of relapse (Supplementary Table 1). The multi-
variate analysis showed advanced disease status (P ¼ .001)
and WBC count greater than 50  109/L (P ¼ .029) were
independently associated with higher incidence of relapse
(Table 3).NRM and Complications
Ten patients (10%) died from transplantation-related
complications at a median of 3.8 months (range, 1.4 to
32.4), resulting in the 2-year cumulative NRM incidence of
12.2% (95% CI, 5.9 to 20.1). Causes were refractory GVHD (1
aGVHD, 2 cGVHD), veno-occlusive disease (n ¼ 2), and in-
fections, whether bacterial (1 sepsis from pyogenic spondy-
litis, 1 bacterial pneumonia), fungal (1 invasive aspergillosis),
or viral (1 meningitis, 1 hepatic failure from hepatitis B virus
reactivation). In univariate analysis, the occurrence of grades
III to IV aGVHD (P ¼ .054) and donor age (P ¼ .054) were
associated with NRM with borderline signiﬁcance
Figure 3. Cumulative incidence of GVHD by donor graft cell dose. (Left) Incidence of grades II to IV aGVHD according to graft CD8þ T cell dose:  (dotted line) versus
> (continuous line) median value of CD8þ (172 cells  106/kg of recipient body weight). (Right) Incidence of moderate to severe National Institutes of Health cGVHD
according to graft CD4þ T cell dose:  (dotted line) versus > (continous line) median value of CD4þ (253 cells  106/kg of recipient body weight).
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only the occurrence of grades III to IV aGVHD was associated
with higher incidence of NRM with borderline signiﬁcance
(Table 3).
CMV reactivation requiring antiviral therapy for pre-
emptive purposes (n ¼ 53) and/or CMV disease (n ¼ 11)
occurred in 72%. In univariate analysis, donor CD8þ cell count
(HR,1.79; 95% CI, 1.03 to 3.11; P¼ .039), male donor (HR,1.67;
95% CI, .95 to 2.96; P ¼ .077), and previous HSCT (HR, 2.04;
95% CI, 1.15 to 3.62; P ¼ .015) were associated with CMV
reactivation requiring preemptive therapy. When adjusted in
multivariate analysis, previous HSCT remained the only sig-
niﬁcant predictor of CMV reactivation. KIR ligand(s)-
mismatch and GVHD had no impact on CMV reactivation
(data not shown).
DISCUSSION
The results of our study are noted in particular by rapid
and sustained engraftment with achievement of complete
donor chimerism in all 80 patients with AML after haplo-
HSCT. The use of G-CSFeprimed PBSCs ensured adequate
yield of donor CD34þ cell dose, whereas fractionated 800 cGy
TBI-based conditioning with low-dose ATG might have pro-
vided sufﬁcient room for donor hematopoietic stem cells to
engraft. By using unmanipulated grafts, we observed only 6%
mortality from infectious causes, with low incidence of NRM
(12%). Our data represent a homogeneous group of patients
in terms of disease type and transplantation-related
procedures.
The use of “mega-doses” of PBSC content with effective
TCD (median, 2  104 CD3þ cells/kg) for haplo-HSCT resulted
in very low rates of aGVHD [35,36], whereas reported inci-
dence of grades II to IV aGVHD after unmanipulated graft
haplo-HSCT ranged around 30% to 40% [19,22,25]. A possible
potential cause for the relatively higher incidence of overall
GVHD in our study using a TCR graft may have come from our
policy of rapid tapering-off of tacrolimus starting from
day þ90 in the absence of severe aGVHD features. All but 2
patients with severe aGVHD (grade III aGVHD in 6 patientsand grade IV aGVHD in 3 patients) were manageable with a
restart of tacrolimus and/or addition of systemic steroid and/
or MMF. Nevertheless, PFS was affected by the occurrence of
severe aGVHD, and we found that a donor graft CD8þ cell
dose was signiﬁcantly related to its incidence.
Although signiﬁcant correlation was seen between doses
of CD4þ and CD8þ cells, a higher number of CD4þ cell doses
was associated with incidence of cGVHD in our study. Higher
donor CD3þ cells in G-CSFeprimed PBSC products have been
suggested to be related to aGVHD or cGVHD in some studies
[37] but not in others [38]. Efﬁcient TCD, typically targeting
less than the critical threshold of 1  105 CD3þ cells/kg of
recipient body weight, is beneﬁcial by means of negligible
severe aGVHD at the expense of delayed immune recovery
with high NRM from infectious complications [13,39].
Although it has been suggested that increasing the Tcell dose
beyond the critical threshold does not necessarily result in
higher incidence of GVHD, the ﬁndings have been demon-
strated in the HLA-matched HSCT setting [40]. Because our
transplantation protocol does not restrict the number of
donor T cells, the median dose of CD3þ cells infused was
relatively higher than other studies [22,24,41,42]. In this
aspect, it is expected that the recent innovative tryouts of
“designed” haplo-grafts to not only separate the graft-
versus-leukemia effect from GVHD but also to facilitate
expansion of donor T cells for long-term immunity will lead
to promising result [16,43,44].
At time of publication, almost all Korean patients, as well
as donors, were seropositive for CMV IgG, a similar situation
in other Asian populations [24,26,45], and show high inci-
dence of CMV reactivation after HSCT [46,47]. Therefore, the
use of extensive TCD grafts or intensiﬁed GVHD prophylaxis
such as post-transplantation cyclophosphamide may cause
concern in terms of fatal CMV infections in populations with
prevalent CMV seropositivity. By infusing large numbers of
peripheral blood progenitor cells from TCR grafts and using
G-CSF after transplantation, a fast hematopoietic recovery
could be achieved in our study. On the other hand, although
the grafts were unmanipulated and tacrolimus was
Figure 4. Transplantation outcomes according to disease status: Probability of (A) OS and (B) PFS and cumulative incidence of (C) relapse and (D) NRM. Shown are
patients with CR1 (n ¼ 52, continuous line), CR2 (n ¼ 17, dotted line), or relapsed/refractory status (n ¼ 11, dashed line) at the time of transplant.
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at 12 months post-transplant in assessable recipients (n ¼
16) was less than 400/mL in our study, similar to what has
been reported after an extensive TCD mismatched
transplant.
The use of G-CSF after allogeneic bone marrow trans-
plantation has beenmetwith concernsmainly because of the
reported risks of GVHD and TRM in some studies, including a
retrospective study of the European Blood and Marrow
Transplantation group [48], whereas most studies on its use
after allogeneic PBSC transplantation did not ﬁnd an increase
in the incidence of GVHD [49]. On the other hand, earlier
studies in animals and human volunteers showed that G-CSF
attenuates the production of proinﬂammatory cytokines
such as tumor necrosis factor-a, IL-12, and IFN-g [50] and
exerts anti-inﬂammatory inﬂuence by increasing IL-10 pro-
duction [51] and promoting T helper 2 immune deviation
[52,53]. Therefore, it may be argued that G-CSF administered
after transplantation could negatively inﬂuence the qualityof post-transplantation immune reconstitution. In fact,
in the setting of TCD haploidentical transplants, post-
transplantation G-CSF administration was stopped subse-
quent to the observation by the Perugia group that it
promoted T helper 2 immune deviation, leading to functional
impairment of immune recovery [15,54-56].
On the contrary, the shift toward an anti-inﬂammatory
cytokine pattern by using G-CSF could be considered an
advantage in the context of the non-TCD PBSC trans-
plantation setting because it may attenuate the risk of
aGVHD [52,53]. Although earlier studies on TCR trans-
plantations found no beneﬁt or disadvantage of giving G-CSF
after transplantations [57,58], most recent studies reported
on transplantation outcome of TCR haplo-HSCT from
numerous centers [19,21,22,26,59-62] have used G-CSF after
transplantation to ensure faster neutrophil recovery, sug-
gesting it is safe to use postgrafting G-CSF in TCR haplo-HSCT.
Future experimental and clinical evidence on functional data
of immune recovery to evaluate the anti-CMV response in a
Table 3
Multivariate Analysis for Transplant Outcomes
Risk Factors n/N Mean  SD at 2 yr (%) HR (95% CI) P
OS
Disease status at HSCT
Standard 9/52 82.5  5.7 1
Advanced 16/28 33.6  10.4 4.35 (1.87-10.08) .001
Occurrence of aGVHD
No aGVHD 19/71 71.1  5.9 1
Grades III-IV aGVHD 6/9 29.6  16.4 2.58 (1.02-6.53) .046
Donor age (continuous variable) d d 1.02 (1.00-1.05) .098
PFS
Disease status at HSCT
Standard 13/52 75.1  6.3 1
Advanced 17/28 34.2  10.0 3.58 (1.68-7.63) .001
Occurrence of aGVHD
No aGVHD 23/71 66.6  6.4 1
Grades III-IV aGVHD 7/9 22.2  13.9 2.89 (1.22-6.88) .016
Donor age (continuous variable) d d 1.02 (.99-1.04) .186
Relapse
Disease status at HSCT
Standard 8/52 16.6  5.5 1
Advanced 21/28 45.8  10.5 4.22 (1.77-10.07) .001
WBC at diagnosis
<50,000 11/57 19.8  5.4 1
50,000 9/23 44.1  11.7 2.69 (1.11-6.54) .029
NRM
Occurrence of aGVHD
No aGVHD 7/71 12.4  4.8 1
Grades III-IV aGVHD 3/9 33.3  17.7 3.35 (.81-13.87) .096
Donor age (continuous variable) d d 1.03 (.99-1.06) .110
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the Tcell receptor diversity and speciﬁcity with acquisition of
immune competence in the presence/absence of GVHD and/
or infection in the setting of TCR haplo-HSCT are needed to
provide better understanding in immune reconstitution
after our transplant approach including the use of post-
grafting G-CSF.
To lower the risk of radiation-induced toxicity but allow
adequate immunosuppression and leukemic cell eradication,
we consistently used a multiple daily fractionated 800 cGy
TBI-based conditioning regimen for adult patients with he-
matologic disorders receiving haplo-HSCT. Previous ran-
domized studies showed that increasing the TBI dose from
1200 to 1575 cGy showed lower relapse rates in AML patients
at the expense of a signiﬁcantly higher early NRM [63,64].
Lowering the TBI dose to 990 cGy was associated with a
higher relapse ratewithout the beneﬁt of reducing NRM [65].
The intensity of 800 cGy is the lowest dose of TBI in MAC
according to some deﬁnitions [66-69], whereas an opera-
tional deﬁnition used by the Center for International Blood
and Marrow Research and the National Marrow Donor Pro-
gram identiﬁed any regimenwith TBI dose of 800 cGy as RIC,
if fractionated [70]. Based on data from several animal
models [71,72], 800 cGy TBI in a single fraction in combina-
tion with thiotepa, cyclophosphamide, and rabbit ATG had
been successfully used in recipients of haploidentical bone
marrow and G-CSFemobilized peripheral blood TCD HSCT,
although lung toxicity was substantial [13,73]. We decided to
adopt 4 doses of 200 cGy TBI (800 cGy) subsequent to
observing poor survival outcome of patients who received
haplo-HSCT using a conditioning regimen consisting of
fractionated 1200 cGy TBI plus ﬂudarabine and busulfan re-
ported in our previous study [10].
In a previous report, we described the feasibility and
favorable outcomes of a RIC regimen consisting of 400 cGy
TBI (with a fraction size of 200 cGy on day1) with the same
doses of ﬂudarabine and busulfan described in this study forAML patients with old age and/or comobidities [74].
Although the rationale for using the dose of fractionated 800
cGy TBI was not conﬁrmed in preclinical tests, we sought to
select an “intermediate” intensity effect from irradiation
based on these clinical experiences. When a fractionated
dosage of 800 cGy TBI combined with cyclophosphamide
(120 mg/kg) was adopted before unrelated HSCT in adult
patients with severe aplastic anemia, we also observed
relatively high OS (88.0%) [31]. Furthermore, the outcome of
a very similar TBI-based conditioning regimen consisting of
four 200 cGy doses of TBI (800 cGy) on days 3 and 2 with
30 mg/m2/day ﬂudarabine daily for 4 days for AML patients
was reported by the Cooperative German Transplant Study
Group, showing this RIC regimenwas feasible with low NRM
and preserved antileukemic activity in allogeneic HSCT from
related or unrelated donors [75]. Also, the results of pro-
spective randomized phase III trial comparing this condi-
tioning regimenwith standard conditioning of 6 doses of 200
cGy of TBI and 120 mg/kg cyclophosphamide showed a
signiﬁcantly lower rate of NRM in the 800 cGy TBI condi-
tioning arm in patients aged 41 to 60 years, although sig-
niﬁcant difference was not found in younger patients [76].
Low NRM (12.2%) with sustained complete donor chimerism
achieved in all patients was demonstrated in this study.
Therefore, although somewhat hypothesis-generating, we
suggest that our unique conditioning regimen of fractionated
800 cGy TBI plus ﬂudarabine/busulfan followed by low-dose
ATG with standard GVHD prophylaxis is safe and may have
provided a well-balanced effect between patient T cell sup-
pression and donor T cell immune reconstitution through a
possible mechanism of tolerable in vivo TCD in unmanipu-
lated grafts using haploidentical PBSC transplantation.
Most importantly, the safety of our haplo-HSCT strategy
was not offset by a high relapse rate, demonstrated by a 3-
year incidence of relapse of less than 20% in patients
receiving transplantation in remission. The 2-year relapse
incidence of 16% in patients in CR1 seems more promising
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ease. Among the 52 patients in CR1, lower incidence of
relapse was seen in a small number of patients (n ¼ 12) with
KIR alloreactivity deﬁned by a ligand-ligand model [77] but
without statistical difference (11.1% versus 18.4%, P ¼ .481;
data not shown). There is a possibility that KIR alloreactivity
would work less prominently under a TCR setting. On the
other hand, the graft-versus-leukemia effect of patients with
cGVHD in our study may have been masked from possible
but obscure (at least in our study) inﬂuence of other immune
cells such as natural killer T cells or regulatory T cells on
decreasing disease recurrence in patients without signs of
cGVHD. As for effects of NIMAs and inherited paternal anti-
gens, we observed no signiﬁcant inﬂuence of either NIMA-
mismatched donors on GVHD or maternal donors on
relapse (data not shown). Because of the small number of
patients, we cannot currently draw any conclusion on a role
of the immune cell subsets or fetomaternal microchimerism
in relation to GVHD aswell as graft-versus-leukemia reaction
from this study. Despite the favorable transplant outcomes in
patients with remission at the time of HSCT, only 1 patient
transplanted in relapsed/refractory status survived without
an event. In the future, a novel strategy is necessary for this
group of patients.
In conclusion, the overall outcomes of HLA-mismatched
related HSCT using unmanipulated PBSCs and our novel
conditioning regimen consisting of 800 cGy TBI, ﬂudarabine,
and busulfanwith standard GVHD prophylaxis added by ATG
were favorable in terms of no primary and secondary
engraftment failure and low incidence of severe GVHD with
favorable PFS, prominently seen in patients with standard-
risk disease status. We are currently undertaking a clinical
trial to prospectively evaluate and demonstrate the efﬁcacy
of our regimen for adult patients with AML receiving allo-
geneic HSCT fromHLA-haploidentical donors comparedwith
that from HLA-matched unrelated donors (#NCT01751997).
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